A combination of two medications, injectable naltrexone and oral bupropion, was safe and effective in treating adults with severe or moderate methamphetamine use disorder in a double, placebo-controlled Phase III clinical trial. The findings suggest this combination therapy might be a promising addition to present approaches to treatment, such as cognitive behavioral treatment and contingency management interventions, for a very serious illness that remains hard to treat and conquer. The study, published today in The New England Journal of Medicine, has been conducted in multiple sites within the National Institute on Drug Abuse Clinical Trials Network (NIDA CTN). NIDA is part of the National Institutes of Health.
There's a lot going on in addition to some of Biden's high-profile moves.
A free no-combat demo goes live on PlayStation 5 today; will hit Xbox, PC later.
Biden Administration starts off with a flurry of orders, actions, and comprehensive plan.
Judge denies injunction motion, says Parler's claims against Amazon are weak.
The French agreement could become a template for similar deals across Europe.
An Advertisement agency sued Omnicom’s DDB, alleging it Had Been’exploited’ to win a $4 billion US Army contract
Summary List PlacementNew York ad agency Hero Group sued Omnicom-owned agency DDB in federal court…